NR4A1 and breast cancer: Also, in a large randomized phase III double blind clinical trial (BIG 1–98) in which hormone receptor-positive patients were undergoing endocrine treatment, receipt of statins was related to longer disease-free-survival (HR 0.79; 95% CI 0.66–0.95; p = 0.01), longer breast cancer-free interval (HR 0.76; 95% CI 0.60–0.97; p = 0.02) and longer distant recurrence-free interval (HR 0.74; 95% CI 0.56–0.97; p = 0.03) [37].